Drug intelligence / Profile preview

UIC201601 + UIC201602

Development stage: Unknown
Lead developer: EvolveImmune United

Overview

UIC201601 + UIC201602 is an investigational combination of two agents, each designated by the code names UIC201601 and UIC201602. The combination has been studied in a drug-drug interaction clinical trial to evaluate their pharmacokinetics and safety when administered together[3][1][8]. There is no publicly available information on the specific molecular identities, mechanisms of action, or therapeutic indications for either agent. The study appears to be early phase (Phase 1), focusing on safety and pharmacokinetic interactions rather than efficacy in a particular disease area.

Beyond the preview

Go deeper on UIC201601 + UIC201602.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on UIC201601 + UIC201602.

Explore the full profile